BACKGROUND: Age-related macular degeneration (AMD) is a progressive disease affecting the macula, the area of the retina that has the highest visual acuity. It can progress to geographic atrophy or choroidal neovascularization. METHOD: Selective literature review. RESULTS: The authors discuss the results of therapeutic trials and the treatment recommendations of the ophthalmological societies. Mechanism-targeted treatments and improved modes of administration offer the potential for improved therapy. CONCLUSIONS: With the advent of the antivascular endothelial growth factor (anti-VEGF) therapy, the prognosis of choroidal neovascularization has changed dramatically. Visual acuity can actually be improved, but, in most cases, the improvement can only be sustained with repeated intravitreal injections.
BACKGROUND: Age-related macular degeneration (AMD) is a progressive disease affecting the macula, the area of the retina that has the highest visual acuity. It can progress to geographic atrophy or choroidal neovascularization. METHOD: Selective literature review. RESULTS: The authors discuss the results of therapeutic trials and the treatment recommendations of the ophthalmological societies. Mechanism-targeted treatments and improved modes of administration offer the potential for improved therapy. CONCLUSIONS: With the advent of the antivascular endothelial growth factor (anti-VEGF) therapy, the prognosis of choroidal neovascularization has changed dramatically. Visual acuity can actually be improved, but, in most cases, the improvement can only be sustained with repeated intravitreal injections.
Authors: Donald J D'Amico; Morton F Goldberg; Henry Hudson; Janice A Jerdan; Scott Krueger; Susan Luna; Stella M Robertson; Stephen Russell; Lawrence Singerman; Jason S Slakter; E Kenneth Sullivan; Lawrence Yannuzzi; Patricia Zilliox Journal: Retina Date: 2003-02 Impact factor: 4.256
Authors: David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Sabine Aisenbrey; Bart A Lafaut; Peter Szurman; Salvatore Grisanti; Christoph Lüke; Ralf Krott; Gabriele Thumann; Julia Fricke; Antje Neugebauer; Ralf-Dieter Hilgers; Peter Esser; Peter Walter; Karl Ulrich Bartz-Schmidt Journal: Arch Ophthalmol Date: 2002-04
Authors: David S Friedman; Benita J O'Colmain; Beatriz Muñoz; Sandra C Tomany; Cathy McCarty; Paulus T V M de Jong; Barbara Nemesure; Paul Mitchell; John Kempen Journal: Arch Ophthalmol Date: 2004-04
Authors: Donald J D'Amico; Morton F Goldberg; Henry Hudson; Janice A Jerdan; D Scott Krueger; Susan P Luna; Stella M Robertson; Stephen Russell; Lawrence Singerman; Jason S Slakter; Lawrence Yannuzzi; Patricia Zilliox Journal: Ophthalmology Date: 2003-12 Impact factor: 12.079
Authors: Juan Liu; Purushottam Jha; Valeriy V Lyzogubov; Ruslana G Tytarenko; Nalini S Bora; Puran S Bora Journal: J Biol Chem Date: 2011-04-22 Impact factor: 5.157
Authors: Aniket Ramshekar; Haibo Wang; Eric Kunz; Christian Pappas; Gregory S Hageman; Brahim Chaqour; David B Sacks; M Elizabeth Hartnett Journal: FASEB J Date: 2021-07 Impact factor: 5.834